Following the publication of this paper, the authors have contacted the Editorial Office to explain that they are unable to reproduce the results of various of their experiments after having repeated some of them, and consequently they wish to retract the paper.owing to a lack of confidence in the presented data. It was also drawn to the attention of the Office that certain of the tumor images shown in Fig. 6A were strikingly similar to data appearing in different form in other articles by different authors. Considering all these points, the Editor of Oncology Reports is in agreement that this paper should be retracted from the Journal. The authors all agree with the decision to retract this paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Oncology Reports 35: 559‑567, 2016; DOI: 10.3892/or.2015.4333].

中文翻译：

---

[已撤稿] MicroRNA-22 通过靶向肾细胞癌中的 SIRT1 作为肿瘤抑制因子。

这篇论文发表后，作者联系编辑部解释说他们重复了一些实验后无法重现他们的各种实验结果，因此他们希望撤回论文。对所提供数据的信心。该办公室还注意到，图 6A 中显示的某些肿瘤图像与不同作者在其他文章中以不同形式出现的数据惊人地相似。考虑到所有这些观点，肿瘤学报告的编辑同意这篇论文应该从期刊上撤回。作者都同意撤回这篇论文的决定。给读者带来的不便，编者深表歉意。【原文发表于肿瘤学报告35：559-567，2016 年；DOI：10.3892/或.2015.4333]。